The Personalized Clinical Trial Support Service Welcomes Five New Patient Associations   

 

Clinical Trials Quebec’s Personalized Clinical Trial Support Service, the newest CATALIS initiative, is available to the following five patient associations: Sickle Cell Anemia Association of Quebec, Ovarian Cancer Canada, Save Your Skin Foundation, Parkinson Québec, and Scleroderma Quebec. These new collaborations aim to provide new patient communities and caregivers with free access to simplified and verified information about available clinical trials. 

“We believe in the strength of our unified community. Collaborating with our partners is crucial to making the greatest impact possible. It is also important for us to serve those who need us most and to reach the largest number of people with ovarian cancer. Ovarian Cancer Canada is proud to partner with Clinical Trials Quebec’s Personalized Clinical Trial Support Service, CATALIS’ newest initiative, to provide the Quebec ovarian cancer community with access to vital resources and information about clinical trials.” – Tania Vrionis, Chief Executive Officer, Ovarian Cancer Canada

 

 

“As General Director of Parkinson Québec, I am aware of the daily challenges faced by people living with this disease and their families. Access to quality clinical trials represents a unique opportunity to participate in the discovery of promising therapeutic solutions and benefit from the best possible care. That is why we are proud to partner with CATALIS, a leader in the field of clinical research in Quebec, which will support us throughout this process.” – Caroline Champeau, General Director, Parkinson Québec

 

 

 

 

 

Through our collaboration with CATALIS, the Save Your Skin Foundation is committed to advancing research and supporting innovation in health. We strive to improve the quality of life of those facing skin health challenges. Together, we have the collective power to bring about meaningful change and remain a driving force for positive impact.Kathleen Barnard, Founder and President, Save Your Skin Foundation

 

 

 

 

 

“We are excited to join Clinical Trials Quebec’s Personalized Clinical Trial Support Service, CATALIS’ newest initiative, because we believe in its potential to make it easier to recruit and refer patients across Quebec. CATALIS is a key stakeholder in Quebec’s clinical research ecosystem and a crucial partner in this exceptional endeavour of facilitating access to high-quality clinical trials. This last point is also vital to paving the way for promising therapeutic solutions and discovering the best possible care.Diane Collard, Executive Director, Scleroderma Quebec

 

 

“Health is not just the absence of illness, but a positive state of well-being that we should feel at all times. As a result, the Sickle Cell Anemia Association of Quebec feels privileged to have access to Clinical Trials Quebec’s Personalized Clinical Trial Support Service, CATALIS’ newest initiative. Through this collaboration, patients suffering from this genetic blood disease called sickle cell anemia can have access to information on available clinical trials in order to benefit from potential treatments more quickly.”– Wilson Sanon, President, Sickle Cell Anemia Association of Quebec

 

 

Clinical Trials Quebec’s Personalized Clinical Trial Support Service, CATALIS’ newest initiative, is now available to 15 patient associations, members of the CATALIS Network.

CATALIS would like to thank the following patient associations for participating on the patient advisory committee and for their commitment to co-developing the Personalized Clinical Trial Support Service’s pilot: Colorectal Cancer Canada, Coalition Priorité Cancer au Québec, Heart and Stroke Foundation, Diabetes Québec, Muscular Dystrophy Canada, Federation of Quebec Alzheimer Societies, Cystic Fibrosis Canada, Quebec Breast Cancer Foundation, Ataxia Charlevoix-Saguenay Foundation, Myeloma Canada, Procure, Regroupement québécois des maladies orphelinesALS Society of Quebec, Arthritis Society of Canada, and MS Canada.

Share: